Imagine living with a condition that can suddenly flare up and disrupt your life. For people with relapsing multiple sclerosis, each relapse can mean lost time, increased disability, and a constant worry about the future. Ponesimod, a medication recently studied, has shown encouraging results over a five-year period. In a long-term study, nearly half of the participants taking ponesimod experienced no relapses, compared to about 40% on a different treatment. This means more patients could enjoy a more stable life without the fear of unexpected flare-ups. While most participants did experience some side effects, the safety profile remained consistent over time, and no new safety concerns emerged. However, it’s important to remember that every treatment comes with risks, and what works for one person may not work for another. As researchers continue to explore ponesimod, it holds promise for many looking for better control of their condition, giving hope for a brighter future in managing multiple sclerosis.
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 YearsCould Ponesimod Change the Game for Multiple Sclerosis Patients?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider ponesimod for sustained RMS control with a favorable long-term safety profile.
This long-term extension (LTE) study of the phase 3 OPTIMUM trial evaluated the safety and efficacy of ponesimod 20 mg in 877 participants with relapsing multiple sclerosis (RMS) over 240 weeks. Participants either continued ponesimod (P20 mg/P20 mg) or switched from teriflunomide to ponesimod (T14 mg/P20 mg). The primary endpoint, annualized relapse rate (ARR), was 0.143 (95% CI: 0.123-0.167) for the continuous ponesimod group compared to 0.184 (95% CI: 0.158-0.213) for the switch group. Secondary endpoints showed that 17.5% of the P20 mg/P20 mg group achieved no evidence of disease activity (NEDA)-3, versus 7.5% in the T14 mg/P20 mg group. Safety assessments revealed that 93.6% of participants experienced at least one treatment-emergent adverse event (TEAE), with serious TEAEs in 12.9% and discontinuations due to TEAEs in 8.6% of participants. The study concluded that ponesimod's effects on disease control are sustained over 5 years with no new safety concerns, supporting its long-term use in RMS management.
What this means for you:
Ponesimod offers hope for better control of relapsing multiple sclerosis, helping more patients avoid relapses. More on Multiple Sclerosis
FDA Approves Kesimpta (ofatumumab) for Relapsing Forms of Multiple Sclerosis in Adults
The FDA approved a new monthly self-injection drug for multiple sclerosis
The FDA has approved Kesimpta, a CD20-directed cytolytic antibody, for the treatment of relapsing forms of multiple sclerosis in adults.
The FDA approved Kesimpta, a new monthly self-injection for adults with relapsing forms of multiple sclerosis.
Aging impacts multiple sclerosis pathobiology by shifting inflammation toward chronic, compartmentalized neuroinflammation and neurodegeneration
New research explores how aging changes multiple sclerosis treatment
This narrative review examines the impact of aging on the immunological and neuroinflammatory microenvironment in older patients with multip…
As people age, multiple sclerosis can change from sudden flare-ups to a slow, steady progression of nerve damage.
Menopause does not appear to be a distinct clinical inflection point for multiple sclerosis progression
Menopause does not appear to be a turning point for MS
This narrative review examines the impact of menopause and biological aging on women with multiple sclerosis. The authors conclude that whil…
While menopause can make symptoms harder to manage, it is not a clear biological turning point for the progression of multiple sclerosis.
Nutrient and metabolite interventions for neurodegenerative diseases show inconsistent clinical translation
Dietary nutrients show mixed results for brain diseases in lab and early human data
This narrative review synthesizes evidence on nutrients and metabolites for Alzheimer's, Parkinson's, multiple sclerosis, and amyotrophic la…
Nutrients like vitamins and marine compounds show promise in labs, but human evidence for brain diseases remains inconsistent and unclear.
View Original Abstract ↓
INTRODUCTION: In phase 3 OPTIMUM study, ponesimod demonstrated superior efficacy and acceptable safety vs teriflunomide in participants with relapsing multiple sclerosis (RMS). This long-term extension (LTE) study was designed to assess the safety and efficacy of ponesimod 20 mg (P20 mg) during extended treatment.
METHODS: Participants who completed core OPTIMUM study entered OPTIMUM-LTE; Participants receiving P20 mg once daily (OD) in core continued with the same dose (P20 mg/P20 mg) and those receiving teriflunomide 14 mg OD switched to P20 mg (T14 mg/P20 mg) in the LTE study. Safety assessments included treatment-emergent adverse events (TEAE). Efficacy was assessed using annualized relapse rate (ARR), time to first confirmed relapse up to end of study (EOS), confirmed disability accumulation (CDA), and magnetic resonance imaging (MRI)-based endpoints.
RESULTS: Of 1133 participants from core study, 877 were enrolled in 240-week LTE study (ponesimod: 439; teriflunomide:438). During LTE, 93.6% of participants in both groups experienced ≥ 1 TEAE; overall, serious TEAEs were experienced by 12.9% of participants (P20 mg/P20 mg: 12.8%; T14 mg/P20 mg: 13.0%) and TEAEs leading to study treatment discontinuation were experienced by 8.6% of participants (P20 mg/P20 mg: 7.7%; T14 mg/P20 mg: 9.4). In combined analysis period, mean ARR was 0.143 (95% CL: 0.123-0.167) for P20 mg/P20 mg and 0.184 (95% CL: 0.158-0.213) for T14 mg/P20 mg; 44.3% of participants in P20 mg/P20 mg and 49.5% in T14 mg/P20 mg experienced relapse. Overall, more participants in P20 mg/P20 mg vs T14 mg/P20 mg group achieved no evidence of disease activity (NEDA)-3 at end of LTE (17.5% vs 7.5%).
CONCLUSIONS: Ponesimod demonstrated extended safety and sustained efficacy over 5 years in participants with RMS, without new safety signals. Results suggest that the effects on the MS disease control are maintained with ponesimod over the LTE treatment period.
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.
Aging impacts multiple sclerosis pathobiology by shifting inflammation toward chronic, compartmentalized neuroinflammation and neurodegeneration
New research explores how aging changes multiple sclerosis treatment
This narrative review examines the impact of aging on the immunological and neuroinflammatory microenvironment in older patients with multip…
As people age, multiple sclerosis can change from sudden flare-ups to a slow, steady progression of nerve damage.
Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response
Trial shows tirofiban improves outcomes for some stroke patients
Intravenous tirofiban significantly improves 90-day functional outcomes for acute ischemic stroke patients failing initial tenecteplase ther…
A new clinical trial suggests that adding tirofiban can improve recovery rates for certain types of stroke patients who do not respond well …
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Postoperative AKI occurs in half of type A aortic dissection surgeries, meta-analysis finds
Factors Linked to Kidney Injury After Aortic Dissection Surgery
This meta-analysis of 44 studies (11,983 patients) found that 50.72% of patients undergoing surgery for Stanford type A aortic dissection de…
Over half of patients undergoing surgery for a specific type of aortic dissection develop acute kidney injury, with several risk factors ide…
Social and emotional skills training shows non-significant reductions in loneliness among children and adolescents
Social and Emotional Training Shows Promise for Youth Loneliness
This meta-analysis of 18 studies evaluated interventions targeting loneliness, including social and emotional skills training, in youth aged…
New research looks at how social and emotional skills training can help reduce feelings of loneliness in children and teenagers.